Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes<xref ref-type="fn" rid="FN1">☆</xref></title><author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F." last="Seymour">John F. Seymour</name><affiliation><nlm:aff id="A1">Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia</nlm:aff></affiliation></author><author><name sortKey="Fenaux, Pierre" sort="Fenaux, Pierre" uniqKey="Fenaux P" first="Pierre" last="Fenaux">Pierre Fenaux</name><affiliation><nlm:aff id="A2">Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris 13 University, France</nlm:aff></affiliation></author><author><name sortKey="Silverman, Lewis R" sort="Silverman, Lewis R" uniqKey="Silverman L" first="Lewis R." last="Silverman">Lewis R. Silverman</name><affiliation><nlm:aff id="A3">Mount Sinai School of Medicine, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Mufti, Ghulam J" sort="Mufti, Ghulam J" uniqKey="Mufti G" first="Ghulam J." last="Mufti">Ghulam J. Mufti</name><affiliation><nlm:aff id="A4">Department of Haematological Medicine, Kings College London, Denmark Hill, London, UK</nlm:aff></affiliation></author><author><name sortKey="Hellstrom Lindberg, Eva" sort="Hellstrom Lindberg, Eva" uniqKey="Hellstrom Lindberg E" first="Eva" last="Hellström-Lindberg">Eva Hellström-Lindberg</name><affiliation><nlm:aff id="A5">Karolinska University Hospital, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Santini, Valeria" sort="Santini, Valeria" uniqKey="Santini V" first="Valeria" last="Santini">Valeria Santini</name><affiliation><nlm:aff id="A6">Hematology, Azienda Ospedaliera Careggi, Firenze, Italy</nlm:aff></affiliation></author><author><name sortKey="List, Alan F" sort="List, Alan F" uniqKey="List A" first="Alan F." last="List">Alan F. List</name><affiliation><nlm:aff id="A7">H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Gore, Steven D" sort="Gore, Steven D" uniqKey="Gore S" first="Steven D." last="Gore">Steven D. Gore</name><affiliation><nlm:aff id="A8">The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Backstrom, Jay" sort="Backstrom, Jay" uniqKey="Backstrom J" first="Jay" last="Backstrom">Jay Backstrom</name><affiliation><nlm:aff id="A9">Celgene Corporation, Summit, NJ, USA</nlm:aff></affiliation></author><author><name sortKey="Mckenzie, David" sort="Mckenzie, David" uniqKey="Mckenzie D" first="David" last="Mckenzie">David Mckenzie</name><affiliation><nlm:aff id="A9">Celgene Corporation, Summit, NJ, USA</nlm:aff></affiliation></author><author><name sortKey="Beach, C L" sort="Beach, C L" uniqKey="Beach C" first="C. L." last="Beach">C. L. Beach</name><affiliation><nlm:aff id="A9">Celgene Corporation, Summit, NJ, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20451404</idno><idno type="pmc">4000027</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000027</idno><idno type="RBID">PMC:4000027</idno><idno type="doi">10.1016/j.critrevonc.2010.04.005</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">002061</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002061</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes<xref ref-type="fn" rid="FN1">☆</xref></title><author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F." last="Seymour">John F. Seymour</name><affiliation><nlm:aff id="A1">Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia</nlm:aff></affiliation></author><author><name sortKey="Fenaux, Pierre" sort="Fenaux, Pierre" uniqKey="Fenaux P" first="Pierre" last="Fenaux">Pierre Fenaux</name><affiliation><nlm:aff id="A2">Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris 13 University, France</nlm:aff></affiliation></author><author><name sortKey="Silverman, Lewis R" sort="Silverman, Lewis R" uniqKey="Silverman L" first="Lewis R." last="Silverman">Lewis R. Silverman</name><affiliation><nlm:aff id="A3">Mount Sinai School of Medicine, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Mufti, Ghulam J" sort="Mufti, Ghulam J" uniqKey="Mufti G" first="Ghulam J." last="Mufti">Ghulam J. Mufti</name><affiliation><nlm:aff id="A4">Department of Haematological Medicine, Kings College London, Denmark Hill, London, UK</nlm:aff></affiliation></author><author><name sortKey="Hellstrom Lindberg, Eva" sort="Hellstrom Lindberg, Eva" uniqKey="Hellstrom Lindberg E" first="Eva" last="Hellström-Lindberg">Eva Hellström-Lindberg</name><affiliation><nlm:aff id="A5">Karolinska University Hospital, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Santini, Valeria" sort="Santini, Valeria" uniqKey="Santini V" first="Valeria" last="Santini">Valeria Santini</name><affiliation><nlm:aff id="A6">Hematology, Azienda Ospedaliera Careggi, Firenze, Italy</nlm:aff></affiliation></author><author><name sortKey="List, Alan F" sort="List, Alan F" uniqKey="List A" first="Alan F." last="List">Alan F. List</name><affiliation><nlm:aff id="A7">H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Gore, Steven D" sort="Gore, Steven D" uniqKey="Gore S" first="Steven D." last="Gore">Steven D. Gore</name><affiliation><nlm:aff id="A8">The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Backstrom, Jay" sort="Backstrom, Jay" uniqKey="Backstrom J" first="Jay" last="Backstrom">Jay Backstrom</name><affiliation><nlm:aff id="A9">Celgene Corporation, Summit, NJ, USA</nlm:aff></affiliation></author><author><name sortKey="Mckenzie, David" sort="Mckenzie, David" uniqKey="Mckenzie D" first="David" last="Mckenzie">David Mckenzie</name><affiliation><nlm:aff id="A9">Celgene Corporation, Summit, NJ, USA</nlm:aff></affiliation></author><author><name sortKey="Beach, C L" sort="Beach, C L" uniqKey="Beach C" first="C. L." last="Beach">C. L. Beach</name><affiliation><nlm:aff id="A9">Celgene Corporation, Summit, NJ, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Critical reviews in oncology/hematology</title><idno type="ISSN">1040-8428</idno><idno type="eISSN">1879-0461</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (≥75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were randomized to AZA (75 mg/m<sup>2</sup>/day subcutaneously×7 days every 28 days) (<italic>n</italic> = 38) or CCR (<italic>n</italic> = 49) and had median ages of 78 and 77 years, respectively. AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; <italic>p</italic> = 0.0193) and 2-year OS rates were 55% vs 15% (<italic>p</italic> < 0.001), respectively. AZA was generally well tolerated compared with CCR, which was primarily best supportive care (67%). Grade 3–4 anemia, neutropenia, and thrombocytopenia with AZA vs CCR were 13% vs 4%, 61% vs 17%, and 50% vs 30%, respectively. Given this efficacy and tolerability, AZA should be considered the treatment of choice in patients aged ≥75 years with good performance status and higher-risk MDS.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8916049</journal-id><journal-id journal-id-type="pubmed-jr-id">1454</journal-id><journal-id journal-id-type="nlm-ta">Crit Rev Oncol Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Crit. Rev. Oncol. Hematol.</journal-id><journal-title-group><journal-title>Critical reviews in oncology/hematology</journal-title></journal-title-group><issn pub-type="ppub">1040-8428</issn><issn pub-type="epub">1879-0461</issn></journal-meta><article-meta><article-id pub-id-type="pmid">20451404</article-id><article-id pub-id-type="pmc">4000027</article-id><article-id pub-id-type="doi">10.1016/j.critrevonc.2010.04.005</article-id><article-id pub-id-type="manuscript">NIHMS490287</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes<xref ref-type="fn" rid="FN1">☆</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Seymour</surname><given-names>John F.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Fenaux</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Silverman</surname><given-names>Lewis R.</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Mufti</surname><given-names>Ghulam J.</given-names></name><xref ref-type="aff" rid="A4">d</xref></contrib><contrib contrib-type="author"><name><surname>Hellström-Lindberg</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name><surname>Santini</surname><given-names>Valeria</given-names></name><xref ref-type="aff" rid="A6">f</xref></contrib><contrib contrib-type="author"><name><surname>List</surname><given-names>Alan F.</given-names></name><xref ref-type="aff" rid="A7">g</xref></contrib><contrib contrib-type="author"><name><surname>Gore</surname><given-names>Steven D.</given-names></name><xref ref-type="aff" rid="A8">h</xref></contrib><contrib contrib-type="author"><name><surname>Backstrom</surname><given-names>Jay</given-names></name><xref ref-type="aff" rid="A9">i</xref></contrib><contrib contrib-type="author"><name><surname>McKenzie</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A9">i</xref></contrib><contrib contrib-type="author"><name><surname>Beach</surname><given-names>C.L.</given-names></name><xref ref-type="aff" rid="A9">i</xref></contrib></contrib-group><aff id="A1"><label>a</label>Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia</aff><aff id="A2"><label>b</label>Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris 13 University, France</aff><aff id="A3"><label>c</label>Mount Sinai School of Medicine, New York, NY, USA</aff><aff id="A4"><label>d</label>Department of Haematological Medicine, Kings College London, Denmark Hill, London, UK</aff><aff id="A5"><label>e</label>Karolinska University Hospital, Stockholm, Sweden</aff><aff id="A6"><label>f</label>Hematology, Azienda Ospedaliera Careggi, Firenze, Italy</aff><aff id="A7"><label>g</label>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</aff><aff id="A8"><label>h</label>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA</aff><aff id="A9"><label>i</label>Celgene Corporation, Summit, NJ, USA</aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel.: +61 3 9656 1076; fax: +61 3 9656 1408. <email>john.seymour@petermac.org</email> (J.F. Seymour)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>10</day><month>7</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>06</day><month>5</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2014</year></pub-date><volume>76</volume><issue>3</issue><fpage>218</fpage><lpage>227</lpage><pmc-comment>elocation-id from pubmed: 10.1016/j.critrevonc.2010.04.005</pmc-comment>
<permissions><copyright-statement>© 2010 Elsevier Ireland Ltd. All rights reserved.</copyright-statement><copyright-year>2010</copyright-year></permissions><abstract><p id="P1">This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (≥75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were randomized to AZA (75 mg/m<sup>2</sup>/day subcutaneously×7 days every 28 days) (<italic>n</italic> = 38) or CCR (<italic>n</italic> = 49) and had median ages of 78 and 77 years, respectively. AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; <italic>p</italic> = 0.0193) and 2-year OS rates were 55% vs 15% (<italic>p</italic> < 0.001), respectively. AZA was generally well tolerated compared with CCR, which was primarily best supportive care (67%). Grade 3–4 anemia, neutropenia, and thrombocytopenia with AZA vs CCR were 13% vs 4%, 61% vs 17%, and 50% vs 30%, respectively. Given this efficacy and tolerability, AZA should be considered the treatment of choice in patients aged ≥75 years with good performance status and higher-risk MDS.</p></abstract><kwd-group><kwd>Azacitidine</kwd><kwd>Low-dose ara-C</kwd><kwd>Elderly</kwd><kwd>Myelodysplastic syndromes</kwd><kwd>MDS</kwd><kwd>Acute myeloid leukemia</kwd><kwd>AML</kwd><kwd>Survival</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002061 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002061 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |